NEW HAVEN, Conn., Dec. 18, 2019 /PRNewswire/ -- Kleo
Pharmaceuticals, Inc., an immuno-oncology company developing
next-generation, fully synthetic bispecific compounds designed to
emulate or enhance the activity of biologics, announced today that
its Chief Executive Officer Doug
Manion, MD, will present at Biotech Showcase 2020, to be
held January 13-15, 2020 at the
Hilton San Francisco Union Square in San
Francisco.
During his presentation, Dr. Manion will provide an overview of
Kleo's development strategy for its pipeline of small molecule and
synthetic peptide compounds that function similar to highly complex
biologics, while offering multiple potential advantages. The
overview will also outline Kleo's key value drivers including its
proprietary technology platforms that drive in-house drug
development and partnership opportunities, the multiple in-house
and collaborative channels through which it is building its
immuno-oncology pipeline and its discovery collaboration with
PeptiDream. Human studies are anticipated in 1H 2020 for Kleo's
first product candidate to move into the clinic, CD38-ARM, a CD38
targeting antibody recruiting molecule (ARM™) to treat multiple
myeloma.
Dr. Manion will also discuss another platform technology at
Kleo, which uses site-directed, chemical conjugation of
off-the-shelf antibodies to enhance or add functionality.
Monoclonal antibody therapy enhancers (MATEsTM) offer a
number of opportunities to optimize or repurpose biologics
currently in development.
Details of the presentation are as follows:
Event:
|
Biotech Showcase
2020
|
Date:
|
Wednesday, January
15, 2020
|
Time:
|
9:30 a.m.
PST
|
Location:
|
Hilton San Francisco
Union Square, San Francisco
|
Room:
|
Franciscan C
(Ballroom Level)
|
About Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals
is a unique immuno-oncology company developing next-generation
bispecific compounds designed to emulate or enhance the activity of
biologics based on the groundbreaking research of its scientific
founder Dr. David Spiegel at Yale
University. Similar to complex biologic drugs, Kleo's
compounds recruit the immune system to destroy cancer cells, with
the advantage of being smaller and more versatile, leading to
potentially improved safety and efficacy over biologics. They are
also much faster and less costly to design and produce,
particularly against novel targets. Kleo is advancing several drug
candidates based on its proprietary technology platforms, all of
which are modular in design and enable rapid generation of novel
immunotherapies that can be optimized against certain cancers, or
enhance the properties of existing immunotherapies. These include
Antibody Recruiting Molecules (ARMs), Synthetic Antibody Mimics
(SyAMs) and Monoclonal Antibody Therapy Enhancers (MATEs). Biohaven
Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc.
(Nikkei:PPTDF) are investors in Kleo Pharmaceuticals. For
more information visit http://kleopharmaceuticals.com.
Forward-Looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve substantial risks and uncertainties, including
statements that are based on the current expectations and
assumptions of the Company's management. All statements, other than
statements of historical facts, included in this press release
regarding the Company's plans and objectives, expectations and
assumptions of management are forward-looking statements. The use
of certain words, including the words "estimate," "project,"
"intend," "expect," "believe," "anticipate," "will," "plan,"
"could," "may" and similar expressions are intended to identify
forward-looking statements. The forward-looking statements are made
as of this date and the Company does not undertake any obligation
to update any forward-looking statements, whether as a result of
new information, future events or otherwise.
CONTACT INFORMATION
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (Investors)
212-375-2664
mmcenroe@tiberend.com
Ingrid Mezo (Media)
646-604-5150
imezo@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kleo-pharmaceuticals-to-present-at-biotech-showcase-2020-300976623.html
SOURCE Kleo Pharmaceuticals, Inc.